Nyxoah S.A.
NYXH

$284.5 M
Marketcap
$8.28
Share price
Country
$-0.12
Change (1 day)
$20.00
Year High
$4.00
Year Low

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

marketcap

Revenue of Nyxoah S.A. (NYXH)

Revenue in 2023 (TTM): $4.35 M

According to Nyxoah S.A.'s latest financial reports the company's current revenue (TTM) is $4.35 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Nyxoah S.A.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $4.35 M $2.69 M $-43,286,000 $-44,657,000 $-43,212,000
2022 $3.08 M $1.93 M $-27,887,000 $-30,056,000 $-31,225,000
2021 $852 K $549 K $-24,580,000 $-24,639,000 $-27,619,000
2020 $69 K $39 K $-10,604,000 $-12,152,000 $-12,245,000
2019 $ $-433,000 $-6,650,000 $-7,185,000 $-7,255,000
2018 $ $-2,523,000 $-8,835,000 $-9,038,000 $-9,079,000
2017 $ $-2,110,000 $-10,119,000 $-10,334,000 $-10,371,000